Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy DrReddys Laboratories (RDY) stocks in Canada

Learn how to easily invest in DrReddys Laboratories stocks.

DrReddys Laboratories is a drug manufacturers-specialty & generic business based in the US. DrReddys Laboratories stocks (RDY.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $73.61 – an increase of 0.44% over the previous week. DrReddys Laboratories employs 22,739 staff and has a trailing 12-month revenue of around $207.3 billion.

How to buy stocks in DrReddys Laboratories

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RDY – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

DrReddys Laboratories stock price (NYSE:RDY)

Use our graph to track the performance of RDY stocks over time.

DrReddys Laboratories shares at a glance

Information last updated 2022-05-20.
Latest market close$55.27
52-week range$47.88 - $74.75
50-day moving average $53.71
200-day moving average $59.75
Wall St. target price$64.47
PE ratio 25.0978
Dividend yield $25 (0.67%)
Earnings per share (TTM) $2.05

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends August 31, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy DrReddys Laboratories stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

DrReddys Laboratories price performance over time

Historical closes compared with the close of $55.27 from 2022-05-26

1 week (2022-05-20) 0.44%
1 month (2022-04-28) 2.92%
3 months (2022-02-28) 3.46%
6 months (2021-11-26) -12.26%
1 year (2021-05-28) -22.56%
2 years (2020-05-28) 7.49%
3 years (2019-05-28) 47.27%
5 years (2017-05-26) 48.26%

Is DrReddys Laboratories under- or over-valued?

Valuing DrReddys Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DrReddys Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

DrReddys Laboratories's P/E ratio

DrReddys Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, DrReddys Laboratories shares trade at around 25x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

DrReddys Laboratories's PEG ratio

DrReddys Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0527. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DrReddys Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

DrReddys Laboratories's EBITDA

DrReddys Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $45.9 billion.

The EBITDA is a measure of a DrReddys Laboratories's overall financial performance and is widely used to measure a its profitability.

DrReddys Laboratories financials

Revenue TTM $207.3 billion
Operating margin TTM 16.75%
Gross profit TTM $103.1 billion
Return on assets TTM 8.11%
Return on equity TTM 14.65%
Profit margin 12.7%
Book value $1,145.05
Market capitalisation $8.6 billion

TTM: trailing 12 months

DrReddys Laboratories share dividends


Dividend payout ratio: 18.72% of net profits

Recently DrReddys Laboratories has paid out, on average, around 18.72% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.67% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), DrReddys Laboratories shareholders could enjoy a 0.67% return on their shares, in the form of dividend payments. In DrReddys Laboratories's case, that would currently equate to about $25 per share.

While DrReddys Laboratories's payout ratio might seem low, this can signify that DrReddys Laboratories is investing more in its future growth.

DrReddys Laboratories's most recent dividend payout was on 11 August 2021. The latest dividend was paid out to all shareholders who bought their shares by 8 July 2021 (the "ex-dividend date").

Have DrReddys Laboratories's shares ever split?

DrReddys Laboratories's shares were split on a 2:1 basis on 7 September 2006. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your DrReddys Laboratories shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for DrReddys Laboratories shares which in turn could have impacted DrReddys Laboratories's share price.

DrReddys Laboratories share price volatility

Over the last 12 months, DrReddys Laboratories's shares have ranged in value from as little as $47.88 up to $74.7492. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while DrReddys Laboratories's is 0.1779. This would suggest that DrReddys Laboratories's shares are less volatile than average (for this exchange).

DrReddys Laboratories overview

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site